Celltrion Pharm Inc
KOSDAQ:068760
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
3.1T KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
978.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.8B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
226.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.9B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.8B USD |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
Celltrion Pharm Inc
Glance View
In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Celltrion Pharm Inc is 7%, which is above its 3-year median of 5.7%.
Over the last 3 years, Celltrion Pharm Inc’s Net Margin has increased from 5.9% to 7%. During this period, it reached a low of 2.9% on Jun 30, 2024 and a high of 8% on Jun 30, 2023.